Adverse effects of corticosteroids on bone metabolism: A review

PM and R

Volumn 3, Issue 5, 2011, Pages 466-471

  Mitra, Raj ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; GLUCOCORTICOID; NERIDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE METABOLISM; BONE REMODELING; CALCIUM INTAKE; FRACTURE; HIGH RISK PATIENT; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK FACTOR; SPINE FRACTURE;

BONE AND BONES; BONE RESORPTION; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; PREDNISONE; RISK FACTORS;

EID: 79955833370     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2011.02.017     Document Type: Article

References (67)

1. Sicard M.A. Les injections medicamenteuseextraduraqles per voie saracoccygiene. C R Seances Soc Biol Fil 1901, 53:396-398.
2. Cathelin F. Mode d'action de a cocaine injete dausl'escapte epidural par le procede du canal sacre. C R Seances Soc Biol Fil 1901, 53:452-453.
3. Cushing H.W. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932, 50:137-195.
4. Lievre J.A., Bloch-Michel H., Pean G., et al. L'hydrocortisone en injection locale. Rev Rhum 1953, 20:310-311.
5. Roberts S.T., Willick S.E., Rho M.E., Rittenberg J.D. Efficacy of lumbosacral transforaminal epidural steroid injections: a systematic review. PM R 2009, 1:657-668.
6. Botwin K., Brown L.A., Fishman M., Rao S. Fluoroscopically guided caudal epidural steroid injections in degenerative lumbar spine stenosis. Pain Physician 2007, 10:547-558.
7. Fowler R.J., Blackwell G.J. Anti-inflammatory steroid induced biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 1979, 278:456-459.
8. Spies C.M., Burmester G.R., Buttgereit F. Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis: a systematic comparison. Clin Exp Rheumatol 2009, 27(Suppl 55):S152-S158.
9. Willenberg H.S., Lehnert H. 2008. Basics and management of glucocorticoid-induced osteoporosis. Internist 2008, 49:1186-1194.
10. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1994, 90:646-650. Consensus Development Conference V, 1993.
11. Brown E.S. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 2009, 1179:41-55.
12. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983, 309:265-268.
13. Soen S., Tanaka Y. Glucocorticoid-induced osteoporosis: skeletal manifestations of GC use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Mod Rheumatol 2005, 15. 163-118.
14. Kerachian M.A., Seguin C., Harvey E.J. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 2009, 114:121-128.
15. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids in the United Kingdom. Q J Med 2000, 93:105-111.
16. Weinstein R.S., Manolagas S.C. Apoptosis in GC-induced bone disease. Curr Opin Endocrinol Diabetes 2008, 12:219-223.
17. Lambrinoudaki I., Kung A.W. Management of steroid-induced osteoporosis. Chin Med J (Engl) 2000, 113:681-685.
18. Hiwatashi A., Westesson P.L. Patients with osteoporosis on steroid medication tend to sustain subsequent fractures. AJNR Am J Neuroradiol 2007, 28:1055-1057.
19. Van Staa T.P., Leufkens H.G., Abenhaim L., Zhang B., Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000, 15:1383-1389.
20. Langhammer A., Forsmo S., Syversen U. Long-term therapy in COPD: any evidence of adverse effect on bone?. Int J Chron Obstruct Pulmon Dis 2009, 4:365-380.
21. Coursin D.B., Wood K.E. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002, 287:236-240.
22. Tuck S.P., Scane A.C., Fraser W.D., Diver M.J., Eastell R., Francis R.M. Sex steroids and bone turnover markers in men with symptomatic vertebral fractures. Bone 2008, 43:999-1005.
23. Olney R.C. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Horm Res 2009, 72(Suppl 1):30-35.
24. Yoshioka T., Sato B., Matsumoto K., Ono K. Steroid receptors in osteoblasts. Clin Orthop Relat Res 1980, 148:297-303.
25. Migliaccio S., Brama M., Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag 2009, 5:305-310.
26. Calder J.D., Buttery L., Revel P.A., Pearse M., Polak J.M. Apoptosis: a significant cause of bone cell death in osteonecrosis of the femoral head. J Bone Joint Surg Br 2004, 86:1209-1213.
27. Dalle Carbonare L., Arlot M.E., Chavassieux P.M., et al. Comparison of trabecular bone microarchitecture and remodeling in GC-induced and postmenopausal osteoporosis. J Bone Miner Res 2001, 16:97-103.
28. De Nijs R.N. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med 2008, 99:23-43.
29. Baron R., Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
30. Delany A.M., Durant D., Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 2001, 15:1781-1789.
31. Ross F.P. Osteoclast biology and bone resorption. Primer on the Metabolic Diseases and Disorders of Mineral Metabolism 2006, 30-35. American Society for Bone and Mineral Research, Washington, DC. M.J. Favus, J.B. Lian, S.R. Goldring (Eds.).
32. Lane N.E., Lukert B. The science and therapy of glucocorticoid induced bone loss. Endocrinol Metab Clin North Am 1998, 27:465-483.
33. Ohlsson C., Vandenput L. The role of estrogens for male bone health. Eur J Endocrinol 2009, 160:883-889.
34. Mohler M.L., He Y., Wu Z., Hong S.S., Miller D.D. Non-steroidal GC receptor antagonists: the race to replace RU-486 for anti-GC therapy. Expert Opin Ther Pat 2007, 17:59-81.
35. Kuroki Y., Kaji H., Kawano S., et al. Short-term effects of GC therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab 2008, 26:271-278.
36. Xu X.H., Dong S.S., Guo Y., et al. Molecular genetic studies of gene identification for osteoporosis: the 2009 update. Endocr Rev 2010, 31:447-505.
37. Hustmyer F.G., Peacock M., Hui S. Bone mineral density in relation to polymorphism at the vitamin D receptor gene locus. J Clin Invest 1994, 94:2130-2134.
38. Sainz J., Van Tornout J.M., Loro M.L. Vitamin D receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 1997, 337:77-82.
39. Clinkscales A., Cleary J.D. Steroid-induced avascular necrosis. Ann Pharmacother 2002, 36:1105.
40. Habib G.S., Saliba W., Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol 2010, 29:347-356.
41. Hein G.E. Particular features of steroid-induced osteoporosis. Orthopade 2007, 36:708. 710-713.
42. Arai K., Hanyu T., Sugitani H., et al. Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study. J Bone Miner Metabol 2006, 24:118-124.
43. Cooper C., Coupland C., Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995, 54:49-52.
44. Compston J. Management of GC-induced osteoporosis. Nat Rev Rheumatol 2010, 6:82-88.
45. Goldstein M.F., Fallon J.J., Harning R. Chronic glucocorticoid therapy induced osteoporosis in patients with obstructive lung disease. Chest 1999, 16:1733-1749.
46. Civitelli R., Ziambaras K. Epidemiology of GC-induced osteoporosis. J Endocrinol Invest 2008, 31(Suppl):2-6.
47. De Vries F., Bracke M., Leufkens H.G.M., et al. Fracture risk with intermittent high dose oral glucocorticoid therapy. Arthritis Rheum 2007, 56:208-214.
48. Van Staa T.P., Leufkens H.G., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
49. Van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
50. Manchikanti L. Role of neuraxial steroids in interventional pain management. Pain Physician 2002, 5:182-199.
51. Kennedy C.C., Papaioannou A., Adachi J.D. Glucocorticoid-induced osteoporosis. Womens Health (Lond Engl) 2006, 2:65-74.
52. Kennel K.A., Drake M.T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009, 84:632-637.
53. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoids-induced osteoporosis. Glucocorticoids-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998, 339:292-299.
54. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42:2309-2318.
55. Benucci M., Saviola G., Baiardi P., et al. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids. Clin Exp Rheumatol 2009, 27:567-573.
56. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of GC-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. HORIZON investigators. Lancet 2009, 373:1253-1263.
57. Reid D.M., Devogelaer J., Saag K., et al. Effect of a single infusion of zoledronic acid 5mg versus oral risedronate 5 mg on bone mineral density at lumbar spine, hip, femoral neck and trochanter in patients with GC induced osteoporosis. J Bone Miner Res 2008, 23:s122.
58. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
59. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
60. Devogelaer J.P., Adler R.A., Recknor C., et al. Baseline GC dose and bone mineral density response with teriparatide or alendronate therapy in patients with GC-induced osteoporosis. J Rheumatol 2010, 37:141-148.
61. Saag K.G., Zanchetta J.R., Devogelaer J.P., et al. Effects of teriparatide versus alendronate for treating GC-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009, 60:3346-3355.
62. Recommendations for the prevention and treatment of glucocorticoids-induced osteoporosis: 2001 updates. Arthritis Rheum 2001, 44:1496-1503. American College of Rheumatology Ad Hoc Committee on Glucocorticoids-Induced Osteoporosis.
63. Adler R.A., Hochberg M.C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003, 163:2619-2624.
64. Luengo M., Pons F., Martinez de Osaba M.J., Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoids therapy for asthma: a two year follow up study. Thorax 1994, 49:1099-1102.
65. Werth V.P. Glucocorticoid-induced osteoporosis evaluation, prevention, and treatment. J Clin Rheumatol 1997, 3(2 Suppl):69-73.
66. Reid I.R. Glucocorticoid-induced osteoporosis: assessment and treatment. J Clin Densitom 1998, 1:65-73.
67. Mori S. Prevalence of steroid osteoporosis. Clin Calcium 2006, 16:1782-1787.